Mirum Pharmaceuticals Inc., a San Diego-based startup picking up the unfinished work of Shire plc's 2014 buy, Lumena Pharmaceuticals Inc., has landed a $120 million series A led by New Enterprise Associates (NEA) to advance what it sees as a viable and well-validated therapy for a pair of rare liver diseases. Its team plans to advance the candidate, maralixibat, into phase III trials next year, targeting progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS).